H. pylori - Ace Infectious
Development of Therapeutic Peptides and Proteins against H. pylori
Services
Online Inquiry

Development of Therapeutic Peptides and Proteins against H. pylori

H. pylori therapeutic peptides and proteins (TPPs), such as antimicrobial peptides, have been found to be promising agents to treat antibiotic-resistant H. pylori. A wide range of antimicrobial peptides is extremely effective in the treatment of antibiotic-resistant bacteria, such as tilapia piscidin 3, Cbf-K16, cathelicidin, and human neutrophil peptide 1. In addition, several TPPs have the ability to inhibit the expression and activity of H. pylori virulence factors. For example, peptides derived from Tetradesmus sp. have active inhibitory activity against three H. pylori virulence factors Cag-A, Vac-A, and Htr-A. Further, for treating H. pylori infection, TPPs have been found to modulate immunity and reduce the inflammatory response. For example, tilapia piscidin 4 can regulate the Th17/Treg ratio to increase host immunity against H. pylori. All of these point to the development needs for TPPs against H. pylori.

Fig. 1 Review of antimicrobial peptides with anti-H. pylori activity based on Neshani et al. (2019).Fig. 1 Review of antimicrobial peptides with anti-H. pylori activity based on Neshani et al. (2019).

Ace Infectious specializes in the development of H. pylori drugs and provides therapeutic peptide and protein development services. We offer two main types of services, which are screening and discovery of H. pylori TPPs and optimization of H. pylori TPPs. We also offer various testing services for H. pylori TPPs. Details of these services can be found in the chapter "Analysis of H. pylori Drugs".

Screening and discovery of H. pylori TPPs

We help to discover TPPs that have the effect of inhibiting the virulence factor of H. pylori, reducing H. pylori colonization, reducing inflammation, and inhibiting the growth of H. pylori. We have established several peptide and protein databases and have established various screening and discovery methods to discover TPPs, including high-throughput screening methods and ligand-receptor development methods. Besides, we have established mature protein extraction and expression systems to assist the discovery of TPPs.

Optimization of H. pylori TPPs

We offer five optimization services to meet the optimization needs of H. pylori TPPs, including stability optimization, optimization to adapt to other expression systems, optimization to improve targeting capability, pH-response activation optimization, and optimization to enhance the disruption of H. pylori cell membranes. We are thoughtful and experienced in the optimization of H. pylori TPPs and we are trustworthy.

Overall, we are uniquely positioned to provide customized services in the discovery and optimization of H. pylori TPPs. Please read the details page to learn more information.

Cooperate with us

H. pylori TPPs showed the activity to treat antibiotic-resistant H. pylori. Many antimicrobial peptides target LPS on the H. pylori cell membrane, which is considered to be difficult to cause resistance. Therefore, the development of TPPs targeting H. pylori is a promising direction for the treatment of antibiotic-resistant bacteria. Ace Infectious offers comprehensive services for the preclinical development of TPPs targeting H. pylori. And we look forward to working with you to realize this valuable drug development and provide you with the most professional services.

References

  1. Neshani, A.; et al. Review of antimicrobial peptides with anti-Helicobacter pylori activity. Helicobacter. 2019, 24(1): e12555.
  2. Sukri, A.; et al. The emergence of multidrug-resistant Helicobacter pylori in Southeast Asia: A systematic review on the trends and intervention strategies using antimicrobial peptides. Antibiotics. 2021, 10(9): 1061.
  3. MubarakAli, D.; et al. Study on the interaction of algal peptides on virulence factors of Helicobacter pylori: In silico approach. Applied Biochemistry and Biotechnology. 2022, 194(1): 37-53.

※ All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.